National Research Corporation
NASDAQ:NRCMedical - Healthcare Information Services
+$0.07 today
- Market cap
- $555.16M
- Beta
- 0.40
- P/E (TTM)
- 43.0
- EPS (TTM)
- $0.41
- Dividend yield
- 3.14%
Volume 0.09M
Average 0.11M
NRC Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
National Research CorporationNASDAQ: NRC
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $34.8M rose 3.7% year over year, ahead of the -1.9% change in trailing-twelve-month revenue. Sequentially, it fell 1.1% from the prior quarter. Over 3 fiscal years it compounded at -3.2% a year.
Context
- Revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 1 analysts of $165M (+20.1%) for the fiscal year ending Dec 2026, a step up from the -4.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $34.8M-1.1% QoQ
- Last fiscal yearDec 2025
- $137.39M-4.0% YoY
- LTMMar 2026
- $138.64M-1.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.7% | +2.5% | -1.2 pp |
| 1 year | -4.0% | +20.1% | +24.1 pp |
| 3-year CAGR | -3.2% | -2.0% | +1.2 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 137.39M USD
- Year-over-year change
- -4.0%
- 4-year CAGR
- -1.8%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 137.39M | -4.0% |
| FY2024 | 2024-12-31 | 143.06M | -3.7% |
| FY2023 | 2023-12-31 | 148.58M | -2.0% |
| FY2022 | 2022-12-31 | 151.57M | +2.4% |
| FY2021 | 2021-12-31 | 147.95M | — |
Revenue vs competitors
How NRC compares with its peers on the latest reported figures
- NRC's LTM Mar 2026 revenue of $138.64M is the 6th highest of the 8 companies compared; the peer median is $302.48M.
- Its year-over-year change of -1.9% is the 6th highest of 8, against a peer median of +6.6%.
- Over three fiscal years its annual growth of -3.2% compares with a peer median of +4.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
CTEVClaritev Corporation | LTM Mar 2026 | $978.76M | +5.5% | -3.7% |
| LTM Apr 2026 | $495.59M | +14.1% | +19.6% | |
| LTM Mar 2026 | $311.78M | +6.6% | +4.5% | |
| LTM Mar 2026 | $302.48M | -2.8% | +4.0% | |
| LTM Mar 2026 | $238.26M | -3.9% | +2.7% | |
| LTM Mar 2026 | $138.64M | -1.9% | -3.2% | |
| LTM Mar 2026 | $124.14M | +10.3% | -4.6% | |
| LTM Mar 2026 | $81.18M | +20.9% | +17.6% | |
| Peer median (excluding NRC) | $302.48M | +6.6% | +4.0% | |
Competitors are the stored peer set for NRC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 147.95M | 151.57M | 148.58M | 143.06M | 137.39M |
| Cost of Revenue | 52.35M | 57.05M | 56.02M | 56.93M | 60M |
| Gross Profit | 95.6M | 94.52M | 92.57M | 86.13M | 77.4M |
| Gross Margin | 64.6% | 62.4% | 62.3% | 60.2% | 56.3% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 38.96M | 42.7M | 46.58M | 44.91M | 54.81M |
| Operating Expenses | 45.33M | 47.98M | 52.52M | 50.93M | 54.81M |
| Depreciation & Amortization | 6.37M | 5.28M | 5.9M | 6.02M | 7.62M |
| EBITDA | 56.66M | 49.3M | 45.99M | 41.31M | 30.23M |
| EBITDA Margin | 38.3% | 32.5% | 30.9% | 28.9% | 22.0% |
| Operating Income | 50.27M | 46.54M | 40.05M | 35.19M | 22.59M |
| Operating Margin | 34.0% | 30.7% | 27.0% | 24.6% | 16.4% |
| Interest Income | 14K | 168K | 820K | 125K | 111K |
| Interest Expense | 1.67M | 1.21M | 862K | 2.6M | 4.76M |
| Other Income / Expenses | (1.65M) | (3.73M) | (83K) | (2.5M) | (4.75M) |
| Income Before Tax | 48.62M | 42.82M | 39.96M | 32.69M | 17.84M |
| Pre-Tax Margin | 32.9% | 28.2% | 26.9% | 22.9% | 13.0% |
| Income Tax Expense | 11.16M | 11.02M | 8.99M | 7.91M | 6.24M |
| Net Income | 37.47M | 31.8M | 30.97M | 24.78M | 11.6M |
| Net Margin | 25.3% | 21.0% | 20.8% | 17.3% | 8.4% |
| EPS (Basic) | 1.47 | 1.28 | 1.26 | 1.05 | 0.52 |
| EPS (Diluted) | 1.46 | 1.27 | 1.25 | 1.04 | 0.52 |
| Weighted Avg Shares | 25.42M | 24.92M | 24.54M | 23.72M | 22.38M |
| Weighted Avg Shares (Diluted) | 25.64M | 25.05M | 24.67M | 23.74M | 22.4M |
National Research Corporation
NASDAQ:NRC
Intrinsic Alpha fair value
Locked
Current Price
$26.16
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.